A PHASE-I DOUBLE BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ORAL WCK 2349 TABLET COMPARED TO PLACEBO IN DOSES OF 600 MG, 800 MG, 1000 MG OR 1200 MG BID ON MULTIPLE DOSE ADMINISTRATION (FOR 5 DAYS) IN HEALTHY ADULT INDIAN HUMAN MALE VOLUNTEERS.

Trial Profile

A PHASE-I DOUBLE BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ORAL WCK 2349 TABLET COMPARED TO PLACEBO IN DOSES OF 600 MG, 800 MG, 1000 MG OR 1200 MG BID ON MULTIPLE DOSE ADMINISTRATION (FOR 5 DAYS) IN HEALTHY ADULT INDIAN HUMAN MALE VOLUNTEERS.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Alalevonadifloxacin (Primary)
  • Indications Bacterial infections; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
    • 10 Apr 2013 Status changed from not yet recruiting to completed as reported by Clinical Trials Registry - India.
    • 13 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top